关于 2025 年前三季度利润分配方案的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 证券代码：688358 证券简称：祥生医疗 公告编号：2025-046 无锡祥生医疗科技股份有限公司 根据无锡祥生医疗科技股份有限公司（以下简称"公司"）《2025 年第三 季度报告》（未经审计），公司 2025 年前三季度合并报表中归属于上市公司股 东的净利润为 93,920,462.46 元；截至 2025 年 9 月 30 日，母公司累计未分配利 润为 282,696,817.53 元。 根据中国证券监督管理委员会《上市公司监管指引第 3 号—上市公司现金 分红》等有关规定及《公司章程》的相关规定，为积极回报股东，与所有股东分 享公司发展的经营成果，结合公司目前总体运营情况和财务水平，在综合考虑投 1 每股分配比例：每 10 股派发现金红利 3 元（含税），不进行资本公积 转增股本，不送红股。 本次利润分配以实施权益分派股权登记日登记的总股本扣减公司回购 专用证券账户中的股份为基数分配利润 ...

Group 1 - The core viewpoint of the article highlights that Xiangsheng Medical (SH 688358) announced its board meeting to discuss the profit distribution plan for the first three quarters of 2025 [1] - For the year 2024, the revenue composition of Xiangsheng Medical is reported to be 99.88% from the medical device industry and 0.12% from other businesses [1] - As of the report, the market capitalization of Xiangsheng Medical stands at 3.3 billion yuan [1]

近5日资金流向一览见下表： 证券之星消息，截至2025年12月12日收盘，祥生医疗(688358)报收于29.58元，下跌0.24%，换手率 0.48%，成交量5383.0手，成交额1598.84万元。 12月12日的资金流向数据方面，主力资金净流入79.42万元，占总成交额4.97%，游资资金净流出1.47万 元，占总成交额0.09%，散户资金净流出77.95万元，占总成交额4.88%。 祥生医疗2025年三季报显示，前三季度公司主营收入3.43亿元，同比下降5.27%；归母净利润9392.05万 元，同比下降4.56%；扣非净利润8696.66万元，同比下降2.69%；其中2025年第三季度，公司单季度主 营收入1.07亿元，同比下降6.68%；单季度归母净利润2422.41万元，同比上升41.95%；单季度扣非净利 润2314.06万元，同比上升53.63%；负债率11.24%，投资收益301.23万元，财务费用-1652.62万元，毛利 率59.82%。祥生医疗（688358）主营业务：超声医学影像设备的研发、制造和销售,为国内外医疗机 构、科研机构、战略合作伙伴等提供各类超声医学影像设备和专业的技术 ...

Investment Rating - The report initiates coverage with a "Buy" rating for the company [3][9] Core Insights - The company is a pioneer in the ultrasound field, focusing on portable and intelligent solutions, with a strong outlook for external collaborations [2][8] - The company has a comprehensive product lineup that includes high-end ultrasound machines and portable devices, which are competitive in both domestic and international markets [8][60] - The financial projections indicate steady revenue growth, with expected revenues of 5.17 billion, 6.21 billion, and 7.45 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 1.46 billion, 1.82 billion, and 2.29 billion yuan [7][9] Summary by Sections 1. Company Overview - Founded in 1996, the company has focused on ultrasound technology, holding over 400 intellectual property rights and exporting products to more than 100 countries [18][21] - The company has established R&D centers in both China and the US, and has been involved in significant national research projects [18] 2. Market Potential - The global ultrasound market is projected to grow, with a compound annual growth rate (CAGR) of 9% expected from 2020 to 2024 [43] - The domestic ultrasound market is also expanding, with significant breakthroughs from local companies [47] 3. Product Development - The company has developed a complete range of ultrasound products, including high-end and portable devices, which are recognized for their performance and innovation [60][67] - The SonoFamily series includes advanced products like XBit90, SonoMax, SonoAir, and SonoEye, which leverage AI technology for enhanced diagnostic capabilities [60][66] 4. Financial Performance - The company has shown stable financial performance, with a projected revenue of 4.69 billion yuan in 2024, despite a slight decline due to external factors [27][32] - The gross margin remains stable at around 59%, with a low debt ratio of 11% as of Q3 2025 [34][38] 5. Strategic Collaborations - The company is actively pursuing external collaborations, including ODM partnerships with major global firms like Philips and the Gates Foundation, which are expected to enhance growth prospects [79][81]

Group 1 - The stock of Xiangsheng Medical (688358) closed at 30.74 yuan on December 5, 2025, with an increase of 1.12% and a trading volume of 4319 lots, amounting to 13.20 million yuan [1] - The net capital flow on December 5 showed a net outflow of 352,700 yuan from main funds, accounting for 2.67% of the total trading volume, while retail funds had a net inflow of 870,100 yuan, representing 6.59% of the total [1] - Over the past five days, the stock experienced fluctuations in capital flow, with varying net inflows and outflows from main, retail, and speculative funds [2] Group 2 - Xiangsheng Medical's total market value is 3.447 billion yuan, with a net asset value of 1.4 billion yuan and a net profit of 93.92 million yuan, ranking 94th, 90th, and 49th respectively in the medical device industry [3] - The company reported a year-on-year decline in main revenue of 5.27% for the first three quarters of 2025, with a net profit decrease of 4.56% [3] - The gross profit margin stands at 59.82%, significantly higher than the industry average of 51.22%, while the net profit margin is 27.37%, compared to the industry average of 9.57% [3] Group 3 - Three institutions have given buy ratings for Xiangsheng Medical in the last 90 days, indicating positive sentiment towards the stock [4] - The definitions of capital flow indicate that inflows are associated with price increases driven by active buying, while outflows are linked to price declines due to active selling [5]

Core Viewpoint - The company announced the appointment of DaXin Accounting Firm as its auditing institution for the fiscal year 2025, taking full responsibility for the company's audit work [2] Group 1 - The company intends to change its auditing firm to DaXin Accounting Firm [2] - The new auditing firm will be responsible for the company's audit work for the fiscal year 2025 [2]

《祥生医疗关于股份性质变更暨2025年限制性股票激励计划股份授予的进展公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年11月28日收盘，祥生医疗（688358）报收于31.61元，较前一交易日上涨0.96%，最新总市值 为35.44亿元。该股当日开盘31.46元，最高31.7元，最低31.05元，成交额达1905.5万元，换手率为 0.54%。 近日，祥生医疗发布关于股份性质变更暨2025年限制性股票激励计划股份授予的进展公告。公告显示， 公司于2025年10月23日确定向17名激励对象授予160,000股限制性股票，授予价格为16.50元/股。因1名 激励对象放弃认购，最终16名激励对象实际认购150,000股，缴款总额为2,475,000.00元。其中148,924股 来源于公司回购股份，1,076股为定向发行。该部分回购股份将由无限售条件流通股变更为有限售条件 流通股，公司总股本不变。相关股份登记手续正在办理中。 最新公告列表 ...

无锡祥生医疗科技股份有限公司 证券代码：688358 证券简称：祥生医疗 公告编号：2025-044 关于股份性质变更暨 2025 年限制性股票激励计划 股份授予的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2025 年 11 月 29 日 为有限售条件流通股，股份来源为公司自二级市场回购的本公司 A 股普通股股 票。公司股本结构变更情况如下： 单位：股 | 证券类别 | 变更前数量 | 本次变更数量 | 变更后数量 | | --- | --- | --- | --- | | 有限售条件流通股 | 0 | 148,924 | 148,924 | | 无限售条件流通股 | 112,124,537 | -148,924 | 111,975,613 | | 合计 | 112,124,537 | 0 | 112,124,537 | 后续，公司将根据相关规定在中国证券登记结算有限责任公司上海分公司办 理本激励计划第一类限制性股票授予的登记工作，并及时履行信息披露义务。 特此公告。 无锡祥生医疗科技股份有限公司董事会 鉴 ...

Core Viewpoint - Xiangsheng Medical (688358) has shown a slight increase in stock price, with a closing price of 31.8 yuan on November 25, 2025, reflecting a 2.12% rise, amidst mixed capital flows from different investor types [1][2]. Financial Performance - For the first three quarters of 2025, Xiangsheng Medical reported a main business revenue of 343 million yuan, a year-on-year decrease of 5.27% [3]. - The net profit attributable to shareholders was 93.92 million yuan, down 4.56% year-on-year, while the non-recurring net profit was 86.97 million yuan, a decrease of 2.69% [3]. - In Q3 2025, the company achieved a single-quarter main business revenue of 107 million yuan, down 6.68% year-on-year, but the net profit attributable to shareholders increased by 41.95% to 24.22 million yuan [3]. Market Position and Ratios - Xiangsheng Medical's total market capitalization is 3.566 billion yuan, with a net asset value of 1.4 billion yuan [3]. - The company has a price-to-earnings (P/E) ratio of 28.47, which is significantly lower than the industry average of 56.62, indicating a potentially undervalued stock [3]. - The gross margin stands at 59.82%, higher than the industry average of 51.22%, while the net profit margin is 27.37%, compared to the industry average of 9.57% [3]. Investor Sentiment - Over the last 90 days, four institutions have rated Xiangsheng Medical with a "buy" recommendation, indicating positive sentiment among analysts [4]. - On November 25, 2025, the net inflow of main funds was 1.7942 million yuan, accounting for 6.04% of the total transaction amount, while retail investors saw a net inflow of 845,500 yuan, representing 2.85% of the total [1][2].

Core Points - Xiangsheng Medical disclosed that as of September 30, 2025, the total number of common shareholders is 6,167 [1] Group 1 - The company will disclose the total number of shareholders and related information in its periodic reports according to the regulations [1]